ホーム > 製品 > 抗体 > バイオシミラー

Research Grade Inebilizumab (HB996026)

データシート製品共有情報コピー

Research Grade Inebilizumab

Research Grade Inebilizumab

Research Grade Inebilizumab

Research Grade Inebilizumab

Research Grade Inebilizumab

Research Grade Inebilizumab

価格(USD): $

スペック:

100ug
1mg

数量:

お問い合わせ

概要
イメージ
参考文献
データシート

概要

カタログ番号	HB996026
説明	Inebilizumab (HB996026) is a research-grade recombinant antibody targeting CD19. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
種反応性	Human
アプリケーション	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
宿主種	Humanized
アイソタイプ	IgG1-kappa
発現システム	Mammalian Cells
クローン性	Monoclonal
ターゲット	CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4
エンドトキシンレベル	Please contact the lab for this information.
純度	>95% purity as determined by SDS-PAGE.
精製	Protein A/G purified from cell culture supernatant.
アクセッション番号	P15391
形態	Liquid
保存バッファー	0.01M PBS, pH 7.4. データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。
安定性と保存	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
別名	CD19, MEDI-551, 1299440-37-1
背景	B-lymphocyte antigen CD19 is a ~61 kDa protein. Functions as a coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens. Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca(2+) stores. Is not required for early steps during B cell differentiation in the blood marrow. Required for normal differentiation of B-1 cells. CD19 is the therapeutic target of tafasitamab (Monjuvi). 1. Vanshylla, K. et al. (2018) Scientific reports 8, 4244. PMID: 29523808 2. Carter, RH. et al. (1992) Science (New York, N.Y.) 256, 105-7. PMID: 1373518 3. van Zelm, MC. et al. (2006) The New England journal of medicine 354, 1901-12. PMID: 16672701 4. de Rie, MA. et al. (1989) Cellular immunology 118, 368-81. PMID: 2463100 5. Wang, Y. et al. (2002) Immunity 17, 501-14. PMID: 12387743 6. Sato, S. et al. (1997) Journal of immunology (Baltimore, Md. : 1950) 159, 3278-87. PMID: 9317126 7. Buhl, AM. et al. (1997) The Journal of experimental medicine 186, 1897-910. PMID: 9382888
注意事項	For research use only. Not suitable for clinical or therapeutic use.

イメージ

Bioactivity

SEC-HPLC detection for Research Grade Inebilizumab.
Bioactivity

Detects Recombinant Human CD19 Protein (Cat No.: ) in indirect ELISA.
SDS-PAGE

SDS-PAGE for Research Grade Inebilizumab.

参考文献

データシート

Research Grade Inebilizumab.pdf

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

=

Concentration

×

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

×

V₁ (Stock Vol.)

=

Working Solution

C₂ (Working Conc.)

×

V₂ (Working Vol.)

レコメンデーション

お問い合わせカスタムクォート、大量リクエストおよびその他の問題については

メール: support@abinScience.com

ディストリビューターリスト

Research Grade Inebilizumab